ResearcherCity of HopeActive in the last 2 years
Byrne Lee
Matched on ORCID iD 0000-0002-1950-0262; OpenAlex author ID A5011687307. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 4
- Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best? Co-author DOI 10.1097/sla.0000000000006609↗
- Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2025.116347↗
- Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: A propensity score-matched analysis. Co-author DOI 10.1002/cam4.2491↗
- Effect of socioeconomic status on surgery for pancreatic adenocarcinoma. Last author DOI 10.1177/000313481207801026↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- George A. Poultsides · 2 shared papers, 2025–2026 · strength 0.42
- Paper Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is B… DOI 10.1097/sla.0000000000006609↗
- Paper Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2025.116347↗
- Daniel Delitto · 2 shared papers, 2025–2026 · strength 0.42
- Paper Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is B… DOI 10.1097/sla.0000000000006609↗
- Paper Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2025.116347↗
- Brendan Christopher Visser · 2 shared papers, 2025–2026 · strength 0.42
- Paper Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is B… DOI 10.1097/sla.0000000000006609↗
- Paper Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2025.116347↗
- Amanda Kirane · 2 shared papers, 2025–2026 · strength 0.42
- Paper Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is B… DOI 10.1097/sla.0000000000006609↗
- Paper Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2025.116347↗
- Jeffrey Allen Norton · 2 shared papers, 2025–2026 · strength 0.42
- Paper Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is B… DOI 10.1097/sla.0000000000006609↗
- Paper Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2025.116347↗
- M. Usman Ahmad · 1 shared paper, 2026 · strength 0.24
- Gregory M. Heestand · 1 shared paper, 2026 · strength 0.24
- Erqi Liu Pollom · 1 shared paper, 2026 · strength 0.24
- Daniel Tandel Chang · 1 shared paper, 2026 · strength 0.24
- George Albert Fisher · 1 shared paper, 2026 · strength 0.24
- Maria Moozhiyil Korah · 1 shared paper, 2025 · strength 0.17
- James Paul Agolia · 1 shared paper, 2025 · strength 0.17
- Deshka S. Foster · 1 shared paper, 2025 · strength 0.17
- Jason L. Guo · 1 shared paper, 2025 · strength 0.17
- Michael Thornton Longaker · 1 shared paper, 2025 · strength 0.17
- Chuner Guo · 1 shared paper, 2025 · strength 0.17
- Laleh Golkar Melstrom · 1 shared paper, 2019 · strength 0.10
- Yuman Fong · 1 shared paper, 2019 · strength 0.10
- Susanne Gray Warner · 1 shared paper, 2019 · strength 0.10
- Vincent M. Chung · 1 shared paper, 2019 · strength 0.10
- Mustafa Raoof · 1 shared paper, 2019 · strength 0.10
- Steven Neema Seyedin · 1 shared paper, 2012 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.